| Name | Title | Contact Details |
|---|
Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.
Champions Oncology is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Vium is the first company to create a living informatics platform for preclinical in vivo drug research.
Prosetta Biosciences, Inc. is an 11-year old biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle. The incorporation of the CFPSS in our drug discovery platform, has lead to the identification of small molecules which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids (the protein shell that protects the DNA or RNA genome of a virus). Prosetta has successfully produced highly potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against Influenza, HIV and HCV.